ReviewNaunyn-Schmiedeberg's archives of pharmacology2024
Thymol as adjuvant in oncology: molecular mechanisms, therapeutic potentials, and prospects for integration in cancer management.
Review in Naunyn-Schmiedeberg's archives of pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- From Plant-Derived Compound to Bioactive Agent in Dentistry: The Expanding Role of Thymol.Dentistry journal · 2026Review
- Thymol as a natural monoterpenoid antibacterial agent: a comprehensive review of applications and current advances.Archives of microbiology · 2026Review
- Dietary Terpenoids in Advancing Biofilm-Mediated Cancer Prevention: Antibiofilm Cascade, Molecular Crosstalk, and Nano-Facilitated Functional Delivery.Cell biochemistry and function · 2026Review
- Sustainable Applications of Thymol: Advances in Formulation Technologies, Drug Delivery Systems, and Food Preservation Strategies.Food science & nutrition · 2026Review
- Coumarin- and Dipicolylamine-Terpenoid Hybrids as Selective Carbonic Anhydrases IX and XII Inhibitors: Mechanistic Insights and Selective Anti-Cancer Potential.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Phytochemistry and Bioactivities of Thymol and Carvacrol: Molecular Pathways, Metabolism, and Therapeutic Insights.Food science & nutrition · 2026Review
- Exploring Thymol's Cytocompatibility and Potential Selective Cytotoxicity in Human Primary Gingival Fibroblasts and Pharyngeal Carcinoma Cells: An In Vitro and In Ovo Investigation.Dentistry journal · 2026Article
- Thymol: properties, synthesis, mechanism of action, and applications.Frontiers in nutrition · 2026Review
- Thymol alleviates silica dioxide nanoparticle-induced reproductive performance toxicity via antioxidant and anti-inflammatory mechanisms in male rats.Scientific reports · 2025Article
- Biological Activity of Monoterpene-Based Scaffolds: A Natural Toolbox for Drug Discovery.Molecules (Basel, Switzerland) · 2025Review
- Antioxidant activity analysis of new interspecific hybrid germplasm thyme and oregano essential oils with different chemotypes.BMC plant biology · 2025Article
- Therapeutic effects ofFrontiers in pharmacology · 2025Article
- Unveiling the Anticancer Potential of Phytocompounds: Pioneering Future Cancer Therapies.Current topics in medicinal chemistry · 2025Review
- Phytochemical Profiling and Therapeutic Potential of Thyme (Food science & nutrition · 2024Review
- Evaluation of the Interaction between Carvacrol and Thymol, Major Compounds ofLife (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains a global health challenge, prompting a search for effective treatments with fewer side effects. Thymol, a natural monoterpenoid phenol derived primarily from thyme (Thymus vulgaris) and other plants in the Lamiaceae family, is known for its diverse biological activities. It emerges as a promising candidate in cancer prevention and therapy. This study aims to consolidate current research on thymol's anticancer effects, elucidating its mechanisms and potential to enhance standard chemotherapy, and to identify gaps for future research. A comprehensive review was conducted using databases like PubMed/MedLine, Google Scholar, and ScienceDirect, focusing on studies from the last 6 years. All cancer types were included, assessing thymol's impact in both cell-based (in vitro) and animal (in vivo) studies. Thymol has been shown to induce programmed cell death (apoptosis), halt the cell division cycle (cell cycle arrest), and inhibit cancer spread (metastasis) through modulation of critical signaling pathways, including phosphoinositide 3-kinase (PI3K), protein kinase B (AKT), extracellular signal-regulated kinase (ERK), mechanistic target of rapamycin (mTOR), and Wnt/β-catenin. It also enhances the efficacy of 5-fluorouracil (5-FU) in colorectal cancer treatments. Thymol's broad-spectrum anticancer activities and non-toxic profile to normal cells underscore its potential as an adjunct in cancer therapy. Further clinical trials are essential to fully understand its therapeutic benefits and integration into existing treatment protocols.
Indexed as
Identifiers
38847831What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.